Ca102n (Not yet branded)
Other Medications
Description
CA102N is an EGFR-targeted therapeutic agent being developed for treatment of metastatic colorectal cancer, particularly in patients with relapsed or refractory disease. It has been evaluated both as monotherapy and in combination with trifluridine/tipiracil (TAS-102) for patients with advanced solid tumors including colorectal cancer. The drug is designed to target EGFR-expressing tumors and has shown potential for use in heavily pretreated metastatic colorectal cancer patients where standard therapies have failed.
Mechanism of Action
CA102N functions as an EGFR inhibitor, blocking the epidermal growth factor receptor pathway that is frequently dysregulated in colorectal cancer. By inhibiting EGFR signaling, the drug disrupts cellular proliferation, survival, and metastatic processes in cancer cells that depend on this pathway for growth.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | IV |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.